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Abstract
Genetic testing has become an increasingly important part of medical practice for heritable form
of cardiomyopathies. Hypertrophic cardiomyopathy and about 50% of idiopathic dilatative
cardiomyopathy are familial diseases, with an autosomal dominant pattern of inheritance.
Some genotype-phenotype correlations can provide important information to target DNA analyses
in specific genes. Genetic testing may clarify diagnosis and help the optimal treatment strategies for
more malignant phenotypes. In addition, genetic screening of first-degree relatives can help early
identification and diagnosis of individuals at greatest risk for developing cardiomyopathy, allowing
to focus clinical resources on high-risk family members.
This paper provides a concise overview of the genetic etiology as well as the clinical utilities and
limitations of genetic testing for the heritable cardiomyopathies.
Background
The success of the Human Genome Project and the recent
discoveries in the area of genetics promise to significantly
change the clinical practice of cardiology, providing new
tools for more accurate diagnosis and prognosis of disease
as well as for a better prediction about health risks for the
family [1,2].
Rapid advances in the technology and reduction in the
cost of DNA sequencing have led to increasingly rapid
translation of genomic information into clinical applica-
tions [3]. As a consequence the number of genetic tests is
growing, and becoming currently available for clinical
testing [4]. However, genetic tests are generally time-con-
suming and expensive, and they should be used with suf-
ficient consideration of their necessity and value in
managing the patient's condition. Therefore, it is impera-
tive that cardiologists know the basis for genetic cardio-
vascular disorders and the medical implications of these
defects in order to improve their expertise as well as to
ensure an appropriate practical use of genetic tests in the
clinical setting. The purpose of this paper is to provide a
concise overview of the genetic etiology as well as the clin-
ical utilities and limitations of genetic testing for the her-
itable form of hypertrophic and dilated
cardiomyopathies.
The genetics of cardiomyopathies
Diseases identified as "genetic" can be typically classified
into two categories: Mendelian diseases and multifactorial
Published: 19 December 2008
Cardiovascular Ultrasound 2008, 6:62 doi:10.1186/1476-7120-6-62
Received: 12 November 2008
Accepted: 19 December 2008
This article is available from: http://www.cardiovascularultrasound.com/content/6/1/62
© 2008 Colombo et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cardiovascular Ultrasound 2008, 6:62 http://www.cardiovascularultrasound.com/content/6/1/62
Page 2 of 10
(page number not for citation purposes)
diseases. Mendelian diseases or monogenic diseases are
rare, and only one mutation in a given gene is responsible
for inheritance of the disease in a given family. Genetic
diseases, in the second group, occur more commonly in
the population and are often recognized as "running in
families" [5]. The genetic model underlying a multifacto-
rial disease is often complex since it may be related to the
interaction or additive effect of multiple genes as well as
to the presence or absence of environmental factors (Fig-
ure 1). Congenital heart disease, coronary heart disease,
venous thrombosis, and diabetes mellitus fall into this
category.
Heritable hypertrophic and dilated cardiomyopathies are
monogenic diseases, caused by mutations in key genes
that lead to the absence or abnormality of myocardial pro-
teins [5].
Disease-causing gene mutations have been identified in
approximately two-thirds of cases of hypertrophic cardio-
myopathy (HCM) and about 50% of idiopathic dilated
cardiomyopathy (DCM).
Various types of mutations can occur in DNA, including
non-sense (stop codons), missense mutations (causing
aminoacid substitution) and splice-site. Mostly, newly
detected mutations for heritable cardiovascular disorders
are missense. For these mutations, it is difficult to estab-
lish their pathogenicity, unless specific functional test are
available. Presently, pathogenicity is presumed when the
substitution affects a very conserved sequence through
evolution, or it was reportedly associated to disease in
independent patients.
The accurate reconstruction of family history is crucial ele-
ment for diagnosis of genetic cardiomyopathy [6].
The family history should encompass at least 3 genera-
tions with a careful and complete history about the family
members, including demographic and medical informa-
tion [7].
The family history may provide additional relevant infor-
mation, such as age of onset and penetrance, and help to
identify the patterns of inheritance (Figure 2).
In addition, information of cardiovascular tests and pro-
cedures (echocardiography, electrocardiography, Holter
monitoring, implantable cardioverter-defibrillator, heart
Single gene disorders or complex traits Figure 1
Single gene disorders or complex traits. A single rare mutation can fully account for a Mendelian disease; clinical variabil-
ity can be, however, observed even for determined monogenic disease, and this variability may itself involve genetic factors, the 
so-called modifier genes. In contrast to monogenic traits, complex traits have many contributing genes and non-genetic influ-
ences.
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Autosomal and X-linked patterns of inheritance Figure 2
Autosomal and X-linked patterns of inheritance. In autosomal dominant inheritance, family history typically reveals that 
the disorder is usually present in every generation, and there is a 50% chance of inheriting the mutation. In autosomal recessive 
inheritance, the condition appears to "skip" generations. Parents of an affected have a 25% chance of having an affected child 
and a 50% chance of having a carrier child in each pregnancy. In X-linked dominant inheritance, all daughters of an affected man 
are affected, sons and daughters of carrier women have a 50% risk of being affected. In X-linked recessive inheritance, there is 
a 50% chance that each son of a carrier woman will also be affected. No male-male transmission is observed.
Dominant  Recessive 
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transplant) should always be recorded as part of the fam-
ily history [6].
However, inherited cardiomyopathies show a wide range
of clinical presentation within the same family, with
incomplete and age-dependent penetrance. Genotype-
phenotype relations are complex and not yet completely
understood. Considerable phenotypic heterogeneity
exists even among individuals who have identical muta-
tions at the disease-causing locus.
Conversely, mutations in different genes can result in a
similar phenotype. The incompleteness of genotype-phe-
notype correlations has limited the use of genetic testing
in clinical practice. In selected cases, DNA target analysis
has, however, potential clinical value, and genetic testing
should be done in patients and families.
Hypertrophic cardiomyopathy (HCM)
Hypertrophic cardiomyopathy (HCM) is a relatively com-
mon and autosomal dominant genetic heart disease
(1:500 of the general population), typically diagnosed by
unexplained left ventricular hypertrophy with 2-dimen-
sional echocardiography (or alternatively with cardiac
magnetic resonance imaging) [8,9]. Left ventricular hyper-
trophy, often disproportionately affecting the ventricular
septum, can range from mild (~13–15 mm) to severe
(30–60 mm). The clinical spectrum of HCM is diverse,
ranging from asymptomatic individuals to those with dis-
abling symptoms of heart failure, exercise intolerance,
arrhythmias and chest pain [9].
Moreover, HCM is the most common cause of sudden car-
diac death (SCD) in the young (including trained ath-
letes), who are often unaware of their underlying
condition. Early diagnosis of HCM is important, since at-
risk individuals may be advised not to participate in com-
petitive sports and should undergo regular cardiac screen-
ing to assess the risk of sudden cardiac death [10].
HCM is caused by a variety of mutations in genes encod-
ing contractile proteins of the cardiac sarcomere, espe-
cially in cardiac myosin heavy chain beta (MYH7),
myosin binding protein C (MYBPC3), and cardiac tro-
ponin T (TNNT2) [8-11]. To date, over 700 individual
mutations have been identified (for a list of gene muta-
tions see http://cardiogenomics.med.harvard.edu/
project-detail?project_id=230.
Mutations in the genes coding for 3 sarcomeric proteins
(MYH7;  MYBPC3;  TNNT2), most commonly are esti-
mated to account for about 60% of all familial cases of
HCM (Table 1). Clinical testing for variants in most of
these genes is available and can provide valuable thera-
peutic and prognostic information.
Overall, clinical diversity of HCM can reflect the broad
spectrum of underlying molecular cause.
Some specific mutations have been recognized to be asso-
ciated with strong clinical effect [10-15]. In particular,
some missense mutations in the gene of the MYH7
(R403Q, R453C, G716R and R719W) were associated
with early onset and poor clinical prognosis, including
sudden death. Moreover, mutations in the TNNT2 gene
(R92Q and ΔE160) have been associated with high inci-
dence of cardiac sudden death in young men, even with
mild hypertrophy. In contrast, patients with mutations in
the MYBPC3 can have a late onset and a relatively good
prognosis [8-11].
Nevertheless, defining precise genotype-phenotype corre-
lations has been limited by the low frequency of each
mutation. Studies of HCM families have also shown the
presence of clinical variability among individual with
identical mutations. Moreover, the clinical presentation
within a given kindred may vary between family mem-
bers, with mild clinical symptoms manifested in one rela-
tive and early-onset heart disease in another. Such
interfamilial variable expressivity may be explained by
genetic and environmental modifying factors. The identi-
fication of other genetic alterations that might play a role
in modulating the presentation of disease is, thus, crucial
in order to improve gene-based diagnosis.
Recently, nonsarcomeric protein mutations in 2 genes
(gamma-2 regulatory subunit of AMP-activated protein
kinase,  PRKAG2, and lysosome-associated membrane
Table 1: Gene mutations in sarcomere-related genes in HCM.
Gene Protein Frequency (%)
MYH7 Cardiac myosin heavy chain beta 30–50
MYBPC3 Myosin binding protein C 20–40
TNNT2 Cardiac troponin T 5–20
TNNI3 Cardiac troponin I <5
TPM1 α-tropomyosin <5
MYL2 Cardiac myosin light chain 2, regulatory <3
MYL3 Cardiac myosin light chain 3, essential <1
ACTC Cardiac actin <1
TTN Titin rare
MYH6 α-myosin heavy chain rareCardiovascular Ultrasound 2008, 6:62 http://www.cardiovascularultrasound.com/content/6/1/62
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protein 2, LAMP2) involved in glycogen accumulation in
cardiac myocytes have also been reported to be responsi-
ble for a less common type of HCM, known as metabolic
HCM [13]. Clinical features of metabolic HCM are also
the high prevalence of electrical abnormalities (ventricu-
lar pre-excitation and atrial fibrillation) and faster pro-
gression from hypertrophy to dilation and severe heart
failure with respect to HCM. Mutations in the PRKAG2 or
in LAMP2 genes are believed to account for about 1% of
all HCM and for up to 50% of HCM with ventricular pre-
excitation [16-18].
Genetic testing for mutant genes is the most definitive
method for establishing the diagnosis of HCM, and some
genotype-phenotype correlations can be useful to address
DNA analyses in specific genes. For example, HCM with
late onset, good prognosis and mild hypertrophy can help
to target DNA analysis for MYBPC3  mutations. Con-
versely, the presence a more malignant phenotype with a
high risk of SCD, may guide genetic screening for MYH7
mutations in the presence of severe hypertrophy or
TNNT2 mutations if the degree of hypertrophy is mild
(Figure 3).
However, caution is required because genotype-pheno-
type correlations are based on a small population. In addi-
tion, the coinheritance of compound mutations (more
than 1 mutation in a single gene, or mutations in 2 differ-
ent genes) is more common than might be expected and
can explain why different families that appear to have the
same mutation can behave differently.
Dilated cardiomyopathy (DCM)
Dilated cardiomyopathy (DCM) is a common (estimated
1:2500 persons) and largely irreversible form of heart
muscle disease; it is the third most common cause of heart
Potential guidelines for genetic test selection in inherited hypertrophic cardiomyopathy Figure 3
Potential guidelines for genetic test selection in inherited hypertrophic cardiomyopathy.
Family History of HCM
in 2 closely related relatives 
Yes No
Yes
genetic testing
Ventricular pre-excitation
Diagnostic DNA-sequence analysis for
PRKAG2, LAMP2, metabolic HCM
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MYH7, MYBPC3, TNNT2
No
genetic testing
Family History of SD
Severe hypertrophy Mild hypertrophy
DNA-sequence analysis for
MYH7
DNA-sequence analysis for
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failure in the young and a major cause of heart transplan-
tation [9].
DCM, diagnosed by 2-dimensional echocardiography, is
characterized by left ventricular dilation and impaired left
ventricular systolic function, often with involvement of
the right ventricle, which then lead to ventricular and
supraventricular arrhythmias, conduction system abnor-
malities, thromboembolism, and sudden or heart failure-
related death.
DCM may derive from a particularly broad range of pri-
mary causes, including infectious agents, toxins, chronic
excessive consumption of alcohol, chemotherapeutic
agents, autoimmune, neuromuscular disorders, mito-
chondrial, metabolic and endocrine disorders.
Approximately one half of patients with the disease are
found to have "idiopathic" DCM, indicating that the
cause for the condition cannot be determined. About one-
third to one-half of "idiopathic" DCM cases has a positive
family history in ≥ 2 closely related relatives. These
patients are considered to have familial dilated cardiomy-
opathy [19].
It is noteworthy that familial DCM is clinically and diag-
nostically the same as other forms of DCM, so careful
attention to family history is essential.
Inheritance patterns of familial DCM include autosomal
dominant, autosomal recessive and X-linked. The auto-
somal dominant forms are the most common inheritance
accounting for about 85–90% of cases.
DCM exhibits high genetic heterogeneity as mutations in
> 20 genes have been associated with the disease, such as
desmin, tafazzin, δ-sarcoglycan, dystrophin, and metavin-
culin, and nuclear envelope proteins such as emerin and
lamin A/C [20].
Mutations in the sarcomere genes, which are responsible
for causing HCM, are also associated with DCM. To date,
sarcomere gene mutations (MYBPC3; MYH7;TNNT2; car-
diac troponin I, TNNI3;  α-tropomyosin,TPM1;  cardiac
actin, ACTC) account for approximately 10–16% of famil-
ial DCM [21,22].
At the present time, genetic screening in all known disease
genes is not possible. However, lamin A/C (LMNA) is the
most frequent disease associated gene for familial DCM
with conduction system disease.
The LMNA  gene encodes the two differentially spliced
proteins lamin A and lamin C, the major components of
the nuclear lamina, which localizes at the nucleoplasmic
surface of the inner nuclear membrane as a meshwork
structure (Figure 4) [23,24]. Lamin interacts directly with
the chromatin and also with the integral proteins of the
inner nuclear membrane, thereby playing a role in main-
taining the structural integrity and spatial organization of
other inner nuclear membrane. During the last years, clin-
ically distinct disease phenotypes have been attributed to
LMNA mutations-termed "laminopathies"-ranging from
accelerated aging disorders to striated muscle diseases like
muscular dystrophy and cardiomyopathy [24,25].
Indeed, the LMNA gene is involved in up to 30–50% of
patients with cardiac conduction disorders and DCM [25-
32]. Although mutations causing DCM can occur almost
anywhere in LMNA, the domain coil 1B seems to be most
frequently affected (Figure 5).
The most prevalent LMNA mutation hot spot in familial
DCM in Europe is codon 190 [32], a missense mutation
(R190W) initially described by Arbustini and colleagues
in an Italian family with severe DCM and SCD [30]. Sub-
sequently, this variant was identified in DCM patients
from other European countries, and even from Korea [33-
35].
A complete list for LMNA  mutations causing DCM is
available in: the Human Gene Mutation Database http://
www.hgmd.cf.ac.uk/ac/index.php, the locus specific
LMNA database http://www.umd.be, and the Leiden Mus-
cular Dystrophy pages http://www.dmd.nl.
A meta-analysis of clinical characteristics of LMNA muta-
tion carriers revealed that LMNA mutations carry a high
risk of sudden death, and that this risk does not differ
between subjects with predominantly cardiac or neu-
romuscular disease [36].
Pasotti et al. have recently shown that dilated cardiomy-
opathies caused by LMNA gene defects are highly pene-
trant, adult onset, malignant diseases characterized by a
high rate of heart failure and life-threatening arrhythmias,
predicted by New York Heart Association functional class,
competitive sport activity, and type of mutation [37].
All these studies indicate that DCM patients with LMNA
mutations show remarkable homogenous clinical pheno-
types with sinoatrial and atrioventricular node dysfunc-
tion, heart block commonly requiring pacemakers, atrial
fibrillation, other supraventricular arrhythmias, sudden
cardiac death, and a malignant course with heart failure
necessitating heart transplantation.
Therefore, it is highly recommended to screen LMNA for
genetic variants when such clinical features are present in
a DCM patient.Cardiovascular Ultrasound 2008, 6:62 http://www.cardiovascularultrasound.com/content/6/1/62
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The LMNA genetic testing may allow useful diagnosis of
mutations clearly correlated with a worse prognosis as
well as identify early "presymptomatic" relatives at great-
est risk for developing DCM (Figure 5).
Potential benefits, disadvantages and 
appropriateness of genetic testing
Genetic testing is often the best way to confirm a diagnosis
in a patient with HCM and DCM, as well as to provide risk
estimates for asymptomatic patients. However, genetic
tests remain generally expensive technologies that are
labour-intensive and time-consuming.
Rapid advances in the technology and reduction in the
cost of DNA sequencing are expected to decrease the costs
and, thus, increase the use of genetic testing, perhaps even
within the next years. At the present time, costs may vary
considerably (from several hundreds to thousands Euro
€) depending on the number of genes and nucleotides
examined. For testing gene in the first family member,
sequencing gene now cost on the order of €1500–€4000.
If a mutation is identified, other family members may be
offered confirmatory testing at a reduced rate that is
around €250.
Therefore, routine and extensive genetic screening is
impractical because of the genetic heterogeneity of cardi-
omyopathies. Genetic testing is not appropriate for every
patient, but it should be used in selected cases, such as
patients with an established family history of severely
affected relatives and at high risk of worse prognosis.
For example, clinical DNA testing for gene mutations
known to be associated with a more malignant phenotype
Schematic representation of the genomic organization of the LMNA gene and localization of most prevalent LMNA mutation hot  spots Figure 4
Schematic representation of the genomic organization of the LMNA gene and localization of most prevalent 
LMNA mutation hot spots. Exon 11 and part of exon 12 encode for lamin A (664 aminoacids) while the alternatively spliced 
part of exon 10 encodes for the lamin C (572 aminoacids) isoform.
Alternative splice
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Lamin C
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Amino terminal
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Central domain
Carboxy terminal
domain
R190W
Head Coil 1a Tail Coil 1 b Coil 2
Head Coil 1a Tail Coil 1 b Coil 2
Improvement of  clinical management of DCM patients 
Better genetic counselling for their relatives
LMNA gene screeningCardiovascular Ultrasound 2008, 6:62 http://www.cardiovascularultrasound.com/content/6/1/62
Page 8 of 10
(page number not for citation purposes)
(e.g. TNNT2 in HCM and LMNA in DCM) can confirm the
diagnosis and help the cardiologist to stratify the risk of
patient.
However, the utility of DNA diagnosis for risk stratifica-
tion is expected to be limited by the genetic and allelic het-
erogeneity of cardiomyopathies. A single gene mutation
does not by itself fully explain the development of the
clinical phenotype. For example, evidence is accumulat-
ing that the combined effect of more than one disease-
associated mutation or genetic polymorphisms, which
contribute to cardiovascular performance, may affect pen-
etrance and severity of the disease in many families.
Anyway, it should be emphasized that genetic screening is
superior to clinical with respect to specificity of identifica-
tion of family members at high risk [38,39].
Genetic testing unambiguously allows early identification
and diagnosis of individuals at greatest risk for developing
cardiomyopathy, allowing to focus clinical resources on
high-risk family members.
In addition, it is extremely important that family mem-
bers receive careful counselling both before and after test-
ing on the potential risks. Relative may carry the mutation
but be asymptomatic and the mutation may merely be a
predisposing factor to disease in the presence of other fac-
tors, and so its presence alone does not allow accurate pre-
diction of phenotype or prognosis. However, if a
mutation is identified in asymptomatic individual, regu-
lar clinical cardiovascular screening (echocardiogram,
ECG) is recommended to detect the first signs of disease
that may be diminished by early treatment.
Flow chart showing the clinical management and the genetic counselling for the heritable cardiomyopathies by a specialised car- diogenetic team Figure 5
Flow chart showing the clinical management and the genetic counselling for the heritable cardiomyopathies 
by a specialised cardiogenetic team.
Clinical diagnosis of
proband with family history
Genetic counselling:
reconstruction of family history
Informed consent and 
genetic testing
Genetic counselling:
results DNA analysis
Disease-causing gene DNA inconclusive
DNA analysis 
first-degree relatives
Individuals
without mutation
No further analysis
High risk members
with mutation
Regular cardiovascular screening
(echocardiogram, ECG)
Stored DNA for future research 
and first-degree clinical screeningCardiovascular Ultrasound 2008, 6:62 http://www.cardiovascularultrasound.com/content/6/1/62
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If family members are found not to carry that mutation,
they can be definitively diagnosed as unaffected, and the
need for serial follow up becomes unnecessary. In this
case, they can be reassured that neither they nor their off-
spring will be at higher risk compared to the general pop-
ulation to develop these disorders.
A specialised cardiogenetic team consisting of clinical
geneticists and cardiologists should work together in
order to provide the most relevant information to the
patients and the relatives, as summarized in Figure 5.
For instance, patients with suspected inherited cardiomy-
opathy are referred to the cardiogenetic team to ascertain
the family history and discuss the importance of molecu-
lar analysis. After informed consent, blood samples are
drawn for DNA analysis. Subsequently, further consulta-
tion with the geneticists can help clarify the interpretation
of the results of the DNA analysis. If the disease-causing
gene cannot be predicted or investigated, DNA is stored
for future research and screening, if permitted by the
patient. If a pathogenic mutation is detected in the
proband, the team provide genetic counselling for family
members with subsequent DNA testing when family
members decide to undergo genetic screening.
Conclusion
Genetic testing has become an increasingly important part
of medical practice for heritable form of cardiomyopa-
thies. HCM and about 50% of idiopathic DCM are famil-
ial diseases. They generally show an autosomal dominant
pattern of inheritance and have underlying mutations in
specific genes; some of these mutations are known to be
associated with a more malignant phenotype. Some gen-
otype-phenotype correlations can provide important
information to target DNA analyses.
Therefore, it is important that physicians develop a spe-
cific knowledge for an appropriate practical use of genetic
screening. In every case, it will crucial to establish a direct
collaboration between geneticists and cardiologists in a
combined clinical setting (cardiogenetics team).
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Glossary of Genetics Terminology
- Chromosomes: single long DNA molecule, whose
regions producing a functional RNA, constitutes a gene.
Somatic cells contain 46 chromosomes, existing as 23 dif-
ferent pairs. One of the chromosomes in each pair is
inherited from the mother, while the other is inherited
from the father.
- Gene: complex functional DNA unit on the chromo-
some that provides instructions for building a protein.
- Allele: a form of a gene. Because chromosomes are
paired, subjects usually carry 2 alleles of each gene.
- Homozygote: an individual with 2 identical alleles of a
specific gene.
- Heterozygote: an individual with 2 different alleles of a
specific gene.
- Phenotype: the observed characteristics of an individual
as defined by genotype.
- Penetrance: the percentage of individuals with a disease-
genotype who express the associated phenotype. Com-
plete penetrance occurs when all individuals who carry
the disease-genotype express the associated phenotype.
- Variable expressivity: the range of different phenotypes
(from mild to severe) associated with a particular geno-
type. Family members may share the same genotype but
present different symptoms or severity.
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